Serological Diagnosis of Idiopathic Pulmonary Alveolar Proteinosis
Takayuki Kitamura(The Cancer Institute Hospital), Koh Nakata(Niigata University Medical and Dental Hospital), Mitsunori Sakatani(NHO Kinki Chuo Chest Medical Center), Atsuyuki Kurashima(The Cancer Institute Hospital), Tomoyuki Tomita(The Cancer Institute Hospital), Otto D. Schoch(The Cancer Institute Hospital), Arata Azuma(Nippon Medical School Hospital), Junichi Watanabe(The Cancer Institute Hospital), Kanji Uchida(The Cancer Institute Hospital), John F. Seymour(The Royal Melbourne Hospital), Shiro Kanegasaki(The Cancer Institute Hospital), Tomoko Tsuchiya(The Cancer Institute Hospital), Shoji Kudoh(Japan Anti Tuberculosis Association), Yoshitsugu Yamada(The University of Tokyo), Ian Doyle(The Cancer Institute Hospital), Kazuo Hanaoka(The Cancer Institute Hospital), Toshihiro Nukiwa(Tohoku University), Naohiko Tanaka(University of Tokyo Hospital), Makoto Katagiri(The Cancer Institute Hospital), Akira Fujita(The Cancer Institute Hospital), Yoshikazu Inoue(Fukujuji Hospital)
American Journal of Respiratory and Critical Care Medicine
August 1, 2000
Cited by 226
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k